Downregulation of miR-483-3p is a poor prognostic marker in NSCLC. The overexpression of miR-483-3p suppresses the malignant phenotypes of NSCLC cells, whose function was reversed by the overexpression of KIF3B.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Research Article
Downregulation of miR-483-3p is a poor prognostic marker in NSCLC. The overexpression of miR-483-3p suppresses the malignant phenotypes of NSCLC cells, whose function was reversed by the overexpression of KIF3B.
MicroRNAs play wide roles in non-small cell lung cancer (NSCLC). To investigate the clinical value of miR-483-3p in NSCLC and its molecular target, 350 NSCLC patients were recruited in this study. RT-qPCR results showed that tumor histological expression of miR-483-3p progressively decreased as the tumor-node metastasis (TNM) stage increased. The receiver operating characteristic (ROC) curve displayed that histological miR-483-3p level can effectively distinguish NSCLC patients with high TNM stage (III) from those with low stage (I+II) (area under the ROC curve = 0.869). The Kaplan-Meier curve showed that NSCLC patients with low miR-483-3p expression demonstrated a lower 5-year overall survival rate. After adjusting for other confounding factors, multivariate Cox analysis further identified miR-483-3p as an independent protective factor for NSCLC survival. Mechanistically, RNA pull-down assay showed that upregulation of miR-483-3p was co-precipitated with KIF3B mRNA and inhibited its expression, thereby suppressing the malignant phenotypes of NSCLC cells and inducing apoptosis. In conclusion, downregulation of miR-483-3p serves as a poor prognostic marker in NSCLC, potentially affecting cancer progression by negatively regulating KIF3B.
Among cancer-related deaths, non-small cell lung cancer (NSCLC) is one of the leading causes. Its high mortality rate is primarily attributed to the aggressive growth of tumors, early metastasis, and the development of acquired resistance1,2,3. Despite advances in current clinical strategies, the overall prognosis for NSCLC patients remains poor4,5,6. In addition to biological challenges, NSCLC patients often experience a heavy symptom burden, including pain, dyspnea, fatigue, and ps....
Access restricted. Please log in or start a trial to view this content.
The Ethics Committee of The Second Affiliated Hospital of Nanjing Medical University approved this study. The fundamental principles of the Declaration of Helsinki have been consistently applied throughout the entire research process. Written informed consent was obtained from all individual participants included in the study. Detailed information on all materials and reagents was provided in the Table of Materials.
Bioinformatics analysis:
The Gene Expression Omnibus database (www.ncbi.nlm.nih.gov) was applied to search the NSCLC-related datasets. GSE171517 is a....
Access restricted. Please log in or start a trial to view this content.
Downregulated miR-483-3p represents a poor prognosis in NSCLC
The Venn diagram (Supplementary Figure 1) indicates that miR-483-3p appears downregulated in both serum samples of NSCLC patients and chemotherapy-resistant NSCLC cell lines. A one-way ANOVA analysis showed that the miR-483-3p expression in the tumor progressively decreased with increasing TNM stage (Figure 1A). ROC curve analysis was performed to evalu.......
Access restricted. Please log in or start a trial to view this content.
This study systematically investigated the miR-483-3p's role in suppressing NSCLC tumors and its underlying mechanism through clinical sample analysis and molecular mechanism exploration. The objective of this study was two folds: (1) to determine whether miR-483-3p serves as an independent prognostic marker in NSCLC, and (2) to elucidate the molecular mechanism by which miR-483-3p may suppress malignant phenotypes through targeting KIF3B. Our findings suggest the clinical value of miR-483-3p as an independent progno.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 0.1% crystal violet | Solarbio/China | G1064 | |
| 0.25% trypsin-EDTA | Gibco/USA | 25200056 | |
| 4% paraformaldehyde | Beyotime/China | P0099 | |
| 7500 Fast RT-PCR system | Applied Bio-systems/USA | 4351106 | |
| A549 | Procell/China | CL-0016 | |
| A549-specific medium | Procell/China | CM-0016 | |
| Annexin V-FITC/PI staining Kit | Beyotime/China | C1062S | |
| BEAS-2B | STEM RECELL/China | STM-CL-5102 | |
| Cell Counting Kit-8 (CCK-8) | Solarbio/China | CA1210 | |
| DMEM medium | MeilunBio/China | PWL003 | |
| Fetal bovine serum | Gibco/USA | A5256701 | |
| GraphPad Prism software | GraphPad | Version 7.0 | |
| H1299 | Procell/China | CL-0165 | |
| H1299-specific medium | Procell/China | CM-0165 | |
| H520 | Procell/China | CL-0402 | |
| H520-specific medium | Procell/China | CM-0402 | |
| HCC827 | Procell/China | CL-0094 | |
| HCC827-specific medium | Procell/China | CM-0094 | |
| KIF3B mRNA | Genscript Biotech/China | customized | |
| Lipo6000 reagent | Beyotime/China | C0526 | |
| miR-483-3p agonist/agonist-NC | MedChemExpress/USA | HY-R01451A | |
| oe-KIF3B/oe-NC | RiboBio/China | customized | |
| Penicillin/streptomycin | Solarbio/China | P1400 | |
| Pierce RNA 3’ End Desthiobiotinylation Kit | Thermo Fisher Scientific/USA | 20163 | |
| PrimeScript RT Reagent Kit (Perfect Real Time) | TaKaRa/Japan | RR037A | |
| si-KIF3B/si-NC | RiboBio/China | customized | |
| SPSS | IBM | Version 23.0 | |
| Streptavidin magnetic beads | New England Biolabs/USA | S1420S | |
| SYBR Green Pro Taq HS Premix | Accurate Biology/China | AG11701 | |
| Transwell chamber | Corning/USA | 3428 | |
| TRIzol reagent | Invitrogen/USA | 15596026CN |
Access restricted. Please log in or start a trial to view this content.